DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* THERACLION *


 

2004 - IDF
Paris
www.theraclion.fr

 

Development, Devices
Key words: Ultrasound, Parathyroidism, Prostate cancer, Fibroadenoma, UNIS
Mission: to develop non-invasive solutions, based on High Intensity Focussed Ultrasound (HiFu), for the non-invasive ablation of small tumors and the treatment of secondary hyperparathyroidism, thyroid nodules
Clients: undisclosed
ismael@theraclion.fr

Age: 12 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Burel (Jean-Yves) [born 1951, ex-GE Healthcare]
Sc.Dir.-CSO: Lacoste (François) [co-founder, born 1950, Eng. physics, ex-Technomed, Cilas-Alacatel, Perkin Elmer]
R&D Dir.-CMO: Yon (Sylvain) [born 1974, ESCPI, Ph.D. physics, ex-Echosens (co-founder)]
Fin.Dir.-CFO:
BusDev: Del Bourgo (David) [Eng. UIT Compiègne, MBA Chicago, ex-Orbotech, Advention Business Partners, General Electric Healthcare]
Financers (Hist.): Truffle Ventures

Turnover (M€) : n.a.
Total funding (M€) : 8.6
Last funding (M€) : 1.6
Focus : Multiple
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .03 Nomination : Jean-Yves Burel, new CEO, replacing Ismaël Nujurally ORGN [7 years]
2012 .01 TH-one for EchoTherapy, renamed as EchoPulse MKTG [7 years]
2011 .11 Clinical trial (phase III) for a non-invasive treatment of breast fibroadenomas (2 patients) CLIN [7 years]
2010 .09 Nomination : Ismaël Nujurally, new CEO, replacing François Lacoste (as CSO) ORGN [6 years]
2009 .02 Financing (no interest loan) : 8.5 M€ (of which 3.5 M€ as grant), OSEO Innovation, as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy DEBT [4 years]
2008 .00 1st round-financing (follow-up) : 1.6 M€, by Truffle Venture RFINA [3 years]
2007 .12 Financing (no interest loan) : 1.3 M€ from OSEO Innovation (together with CE Mark approval) DEBT [3 years]
2006 .03 Clinical trial (phase II) for a non-invasive treatment of thyroid nodules (beginning) CLIN [1 year]
2005 .04 1st round-financing : 3.5 M€, by Truffle Venture RFINA [0 year]
2004 .08 Company founded by François Lacoste (CEO), Gérard Hascoët [Promed, Sometec, IMMI, Technomed International], Jean Louis Hervy [Sapex, SMI], Annie Claude Benichou [M.D.], Guillaume Olivier Doré ORGF [0 year]

Actualisation / Updating: 7-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende